

Research Paper

International Journal of Medical Sciences

2020; 17(5): 664 - 677. doi: 10.7150/ijms.41999

Global Analysis of miRNA Signature Differentially Expressed in Insulin-resistant Human Hepatocellular Carcinoma Cell Line

Linjing Li¹*^[2], Yan Cheng²*, Li Lin³*, Zhuan Liu¹, Shengfang Du⁴, Li Ma¹, Jing Li¹, Zhiheng Peng¹, Jing Yan¹

1. Department of Clinical Laboratory Center, The Second Hospital of Lanzhou University, Lanzhou 730000, P.R. China.

- 2. Northwest University for Nationalities, Lanzhou 730000, P.R. China.
- 3. Hematology Department, Gansu Provincial Cancer Hospital, Lanzhou, Gansu 730000, China.
- 4. Department of Anesthesiology, the Second Hospital of Lanzhou University, Lanzhou 730000, P.R. China.

*These authors contributed equally to this article.

🖂 Corresponding author: Linjing Li, Department of Clinical Laboratory Center, The Second Hospital of Lanzhou University, 82 Cuiying Gate Road, Lanzhou, Gansu, 730000, P.R. China, E-mail: lilinj@lzu.edu.cn.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2019.11.11; Accepted: 2020.02.21; Published: 2020.02.24

Abstract

Chemoresistance mediated by insulin resistance (IR) in HCC has already been validated. However, the underlying mechanism, especially the involvement of microRNAs (miRNAs) was unelucidated. In this study, miRNA microarrays and bioinformatics methods were employed to determine the dysregulation of miRNA by IR in HCC cells, and quantitative RT-PCR (qRT-PCR) was applied to valid the miRNA array data. Of all the 2006 miRNAs screened, 32 miRNAs were found up or down regulated between the HepG2/IR cells and its parental cells. Further literature mining revealed that some of these miRNAs may function as oncogenes or tumor suppressors that contribute to tumor progression, recurrence, and metastasis which eventually lead to chemotherapeutic resistance. Interestingly, bioinformatics analysis by Gene Ontology (GO) enrichment pathway indicating that function of the predicted target genes of these dysregulated miRNAs were significantly enriched in the processes related with biosynthesis, catabolism, modification etc., and Kyoto Encyclopedia of Genes and Genomes (KEGG) mapping showed that the biological regulatory mechanisms were integrated in cancer-related pathways. Moreover, we also constructed a network which connected the differentially expressed miRNAs to target genes, GO enrichments and KEGG pathways to reveal the hub miRNAs, genes and pathways. Collectively, our present study demonstrated the possible miRNAs and predicted target genes involving in the pathophysiology of insulin resistant HCC, providing novel insights into the molecular mechanisms of multidrug resistance in the insulin resistant HepG2 cells.

Key words: insulin resistance, HCC, miRNA Signature

Introduction

Hepatocellular carcinoma (HCC) is one of the most common cancers with high mortality rates worldwide [1]. Unfortunately, some HCC patients are not eligible for radiofrequency ablation or surgical resections, thus must only rely on chemotherapy. However, the inherent multidrug resistance (MDR) towards chemotherapeutics often impairs the effect of chemotherapy for HCC therefore cannot produce satisfactory clinical outcomes [2]. Drug resistance is a multifactorial phenomenon involving many mechanisms, such as T2DM and IR caused by tumorigenesis and inflammation in the liver [3-5]. Our previous studies also validated that IR enhances the tolerance of HCC cells to chemotherapeutic [6-9], indicating that IR contributes to the inherent MDR of HCC. Nevertheless, the key underlying mechanism of the acquisition of resistance to chemotherapeutic drugs still remain largely unexplored.

miRNAs are endogenously expressed small noncoding RNAs with 18-25 nucleotides which play a vital role in the regulation of gene expression at posttranscriptional level [10]. Emerging evidences have revealed that miRNAs are important modulators in many signaling pathways involved in tumorigenesis [11]. Furthermore, significant variation with miRNA expression were observed in drug tolerant cancer cells in comparison with their parental drug sensitive cancer cells which displays as higher expression of cancer-promoting miRNAs (oncomiRNAs) and lower expression of cancer-inhibiting miRNAs (tumor suppressor miRNAs) [12]. They might serve as tumor suppressors or oncogenes and constitute ideal targets in exploring anticancer therapeutics [13]. miRNAs have been showed as regulators that can promote or impair drug resistance in several cancers including HCC. Kabir TD et al reported that miR-7 could overcome sorafenib resistance by suppressing its target TYRO3 via PI3-Kinase/AKT pathway [14]. Xia H etc. declared that miR-216a/217 could activate TGF-β pathway to induce sorafenib resistance [15]. Meng W etc. believed that inhibition of the expression of miR-33a-5p could reduce cisplatin sensitivity and increased its drug resistance in HCC [16]. Another group identified the role of miR-195 in developing drug resistance in HCC cell line [17]. They found that it might improve 5-FU sensitivity by targeting Bcl-w protein to increase cell apoptosis. It was also reported that miR-3129-5p and its target gene Zeb1 endow HCC cells a tolerance to doxorubicin [18]. Due to the important role of miRNAs in the development of drug resistance of HCC, it is useful to employed global and systematic analytic techniques to assess the miRNA expression profiles in the drug resistant HCC cells.

Chemoresistance mediated by insulin resistance in HCC have already been validated by our previous studies [6-9], while little was known concerning the role of miRNAs in IR-mediated chemotherapy resistance. Thus, in the current study, comprehensive expression profiling of miRNAs by microarray was performed in insulin-resistant and parental HCC cell lines. Differentially expressed miRNA were identified between these two cell lines with bioinformatics analyses, which may contribute to a better understanding of the potential role of miRNAs in multidrug resistance of the insulin-resistant HCC cells.

Materials and Methods

Cell culture

Human hepatocellular carcinoma HepG2 cells were purchased from American Type Culture

Collection (ATCC HB-8065, Rockville, MD, USA) and cultured in Dulbecco's modified eagle medium (DMEM) supplemented with 10% FBS at 37 °C with 5% CO₂. IR was induced in HepG2 cells according to the method described previously [7]. Briefly, cells were incubated in serum-free DMEM for 6 hr to synchronization then treated with insulin at a concentration of 0.5 μ M for 72 hr. The resultant cells were named as HepG2/IR cells.

RNA extraction

Total RNAs from each sample were individually isolated using QIAzol Lysis Reagent and miRNeasy mini kit (Qiagen Inc, Valencia, CA, USA) according to the manufacturers' instructions. This procedure efficiently recovered all types of RNAs, including miRNAs. RNA quantity and quality were measured using a NanoDrop spectrophotometer (ND-1000; Nanodrop Technologies, Wilmington, DE, USA) and RNA integrity was detected by gel electrophoresis.

Affymetrix GeneChip miRNA Array Hybridization

For analysis with Affymetrix GeneChip miRNA Arrays (Affymetrix, Santa Clara, CA, USA), each sample was prepared with 150 ng of total RNAs. Samples were labeled with the FlashTag Biotin HSR labeling kit (Affymetrix, Santa Clara, CA, USA) according to the manufacturer's instructions. The RNA sample was mixed into the Poly A Tailing master mix, and FlashTag[™] Biotin HSR Ligation was performed by adding FlashTag Biotin HSR Ligation Mix to each of the tailed RNA samples. T4 DNA Ligase was added to each sample for labeling reaction. The hybridization cocktail was then added to each labeled sample, the resultant mix of each sample was applied to an array on the Affymetrix GeneChip miRNA 4.0 Arrays, the probe arrays were washed and stained, then scanned and analyzed using the Affymetrix GeneChip Fluidics Station 450. Differentially expressed miRNAs were identified using fold changes as well as P values calculated by the Student's t-test. The thresholds set for up and down regulated miRNAs were a fold change ≥ 2.0 and P ≤ 0.05 .

Bioinformatics analysis

Potential target genes of differentially expressed miRNAs were predicted using DIANA-miRPath online software [19], with Micro T threshold set at 0.8 and P-value threshold set at 0.05. The predicted target genes subsequently underwent Gene Ontology (GO) analysis for functional annotation analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) database analysis to identify the enriched functions and pathways that might be involved. Fisher's exact and Chi-square tests were used to determine the significance of the GO and KEGG terms and pathways. Only the KEGG terms with a P-value<0.01 and GO terms with a P-value<1E-10 were selected.

miRNA-gene network analyses

To improve the understanding of the associations between the differentially expressed miRNAs and its target genes, miRNA-gene network was constructed according to the regulatory associations between miRNAs and target genes. The associations of the genes and miRNAs were constructed by Cytoscape 3.7.2 software. The output degree was used to measure the regulated effect of miRNAs on genes or effect of genes on miRNAs.

miRNA-GO network analysis

The miRNA-GO network was constructed according to the significantly expressed miRNAs and the results of the GO analysis. The degree of miRNAs indicated the number of GOs which were regulated by the miRNA in the network. In the same way, a higher degree of GO indicated that more miRNAs involved in the GO category. Similarly, a higher degree of miRNA suggested more GO categories related with certain miRNA.

miRNA-KEGG network analysis

A miRNA-KEGG network was constructed according to the specifically regulated miRNAs and the KEGG analysis. The degree of miRNAs indicated the number of KEGG pathways which was regulated by the miRNA in the network. In the same way, a higher degree of KEGG indicated that more miRNAs involved in the KEGG pathway.

Quantitative reverse transcription polymerase chain reaction (qRT-PCR)

To validate the authenticity of miRNA expression detected by microarray assay and the crucial predicted target genes of these miRNAs, 14 differentially expressed miRNAs were analyzed by qRT-PCR, including down-regulated miRNAs such: as hsa-miR-134-5p, hsa-miR-5195-3p, hsa-miR-641, hsa-miR-3935 and; up-regulated miRNAs such as hsa-miR-1231 (ID: hsmq-0529), hsa-miR-6726-5p (ID: hsmq-2842), hasmiR-3180 (ID: hsmq-1188), sa-miR-3613-5p (ID: hsmq-1112), hsa-miR-6779-5p (ID: hsmq-2840), hsa-miR-7111-5p (ID: hsmq-2216), hsa-miR-6870-5p (ID: hsmq-2604), hsa-miR-6813-5p (ID: hsmq-2845), hsamiR-4492 (ID: hsmq-1344) and hsa-miR-4505 (ID: hsmq-1358). For this analysis, the miRNAs were detected using the All-in-One[™] miRNA qRT-PCR Detection Kit (GeneCopoeia, Rockville, MD, USA) according to the manufacturer's instructions. Item ID of each primer is showed before. qPCR was performed using SYBR-Green (Thermo Fisher Scientific, Inc.)

reagent according to the manufacturer's instructions in the ABI 7300 real-time qPCR system (Thermo Fisher Scientific, Waltham, MA, USA). The relative abundance of each miRNA was calculated by the comparative Ct method ($2-\Delta\Delta$ Ct), and the results were assessed by using a t-test.

Statistical analysis of qRT-PCR result

All quantitative data were presented as means \pm standard deviations. Comparisons between HepG2/IR and it parental cells were performed using the Student's t-test. P-values <0.05 were considered statistically significant. Statistical values were calculated using SPSS software, version 20.0 (IBM Corp, Armonk, NY, USA).

Results

miRNA microarray analysis

To identify the differentially expressed miRNAs between HepG2/IR cells and its parental cells, both cell lines were subjected to the Affymetrix microRNA 4.0 array in triplicate. The results revealed that, of all the 2006 miRNAs screened, 32 miRNAs were dysregulated in HepG2/IR cells compared with its normal control (Table 1) under the condition of 'fold change>2 and P<0.05'. Among these 32 miRNAs, 27 were up-regulated and 5 were down-regulated. An unsupervised 2D-cluster analysis was applied for these two cell lines (Fig. 1) Volcano plot of significantly expressed miRNAs between HepG2/IR and HepG2 cells were showed in Fig. 2 and the 32 of them were highlighted.

Target genes and bioinformatics analysis

A total of 5,406 genes were predicted as target genes of the identified 32 differentially expressed miRNAs (Table S1). To better understand the potential implications of these dysregulated miRNAs, the target genes were subjected to GO analysis to evaluate their potential functions using DIANA-miRPath v3.0 online software (http://snf-515788.vm.okeanos.grnet. gr/). In the present study, the top GO terms of the target genes of the dysregulated miRNAs were regulation of cellular nitrogen compound metabolic process, biosynthetic process, cellular protein modification process (BP); cellular component, protein complex, cytosol (CC); ion binding, transcription coactivator activity, molecular function, nucleic acid binding transcription factor activity (MF) (Fig. 3, Table S2).

The target genes were also subjected to KEGG pathway enrichment analysis using DIANA-miRPath v3.0 online software (http://snf-515788.vm.okeanos.grnet.gr/) to determine the canonical pathways controlled by the identified miRNAs. Other types of

O-glycan biosynthesis, proteoglycans in cancer, adrenergic signaling in cardiomyocytes, estrogen signaling pathway, cell adhesion molecules, glycosphingolipid biosynthesis, glycosaminoglycan biosynthesis, and ErbB signaling pathway were the most active pathways that the target genes of the differentially expressed miRNAs may be involved. (Fig. 4, Table S3).

miRNA-gene-network analyses

A miRNA-gene network was constructed according to the results of the GO and KEGG pathway analyses. The core miRNAs of the interaction network include miR-6870-5p, miR-7111-5p, miR-4505, miR-4492 and miR-641 (Table 2). The network also revealed that Kinase suppressor of Ras 2 (KSR2), Ras/ Rap GTPase-activating protein SynGAP (SYNGAP1), Glutamate receptor ionotropic (GRIN2B), G proteinactivated inward rectifier potassium channel 2 (KCNJ6), and Complexin-2 (CPLX2) were the most crucial target genes (Table 3, Table S1). The associations of miRNAs with genes were shown in Fig. 5.

 Table 1. Differentially expressed microRNAs (miRNAs) between

 HepG2/IR cells and its parental control (p<0.05, Fold change>2)

miRNA	p-value	Fold Change	Type of regulation
hsa-miR-3613-5p	0.0242590	6.28	Up
hsa-miR-6813-5p	0.0123839	6.12	Up
hsa-miR-6132	0.0099436	4.05	Up
hsa-miR-4492	0.0160402	3.59	Up
hsa-miR-3937	0.0468370	3.36	Up
hsa-miR-7112-5p	0.0283560	3.31	Up
hsa-miR-6795-5p	0.0137803	3.28	Up
hsa-miR-6726-5p	0.0052162	3.11	Up
hsa-miR-6848-5p	0.0044207	3.07	Up
hsa-miR-6870-5p	0.0001978	3.01	Up
hsa-miR-7111-5p	0.0247380	2.94	Up
hsa-miR-6780b-5p	0.0398410	2.90	Up
hsa-miR-6782-5p	0.0193971	2.82	Up
hsa-miR-3180	0.0482000	2.73	Up
hsa-miR-4467	0.0296810	2.72	Up
hsa-miR-6805-5p	0.0174751	2.66	Up
hsa-miR-6846-5p	0.0231760	2.54	Up
hsa-miR-4706	0.0456770	2.48	Up
hsa-miR-4505	0.0307830	2.38	Up
hsa-miR-8072	0.0176760	2.37	Up
hsa-miR-6085	0.0333000	2.28	Up
hsa-miR-4649-5p	0.0200810	2.25	Up
hsa-miR-6757-5p	0.0040993	2.23	Up
hsa-miR-6779-5p	0.0167355	2.18	Up
hsa-miR-3621	0.0468600	2.13	Up
hsa-miR-1231	0.033018	2.08	Up
hsa-miR-4508	0.0143212	2.04	Up
hsa-miR-641	0.027156	-2.23	Down
hsa-miR-4793-5p	0.0133985	-2.27	Down
hsa-miR-134-5p	0.040759	-2.95	Down
hsa-miR-5195-3p	0.00055787	-3.30	Down
hsa-miR-3935	0.030403	-3.55	Down

Table	2.	Crucial	microRNAs	(miRNAs)	in	the	miRNA-target
networ	k (c	degree >	3)				

miRNA	Degree
hsa-miR-6870-5p	87
hsa-miR-7111-5p	67
hsa-miR-4505	66
hsa-miR-4492	57
hsa-miR-641	52
hsa-miR-6780b-5p	50
hsa-miR-5195-3p	48
hsa-miR-6846-5p	46
hsa-miR-6848-5p	45
hsa-miR-6779-5p	41
hsa-miR-6795-5p	27
hsa-miR-6132	26
hsa-miR-134-5p	22
hsa-miR-3613-5p	19
hsa-miR-1231	18
hsa-miR-4793-5p	17
hsa-miR-6085	17
hsa-miR-6813-5p	16
hsa-miR-6782-5p	14
hsa-miR-3935	13
hsa-miR-6757-5p	13
hsa-miR-6726-5p	8
hsa-miR-6805-5p	8
hsa-miR-3180	4

miRNA-GO network analysis

miRNA-GO network The analysis was favourable for determining regulatory associations between the key miRNAs and hub GO. In this network, miR-4492, miR-641 and miR-6779-5p, which contributed more than the other specifically expressed miRNAs exhibit 114, 114 and 113 GO functions, respectively (Table 4, Table S4). The most significantly regulated functional clusters of total categories were cellular nitrogen compound metabolic process, biosynthetic process, biological process and catabolic process (Table 5). The significantly complicated categories associations of miRNAs with degree more than 25 were shown in Fig. 6.

miRNA-KEGG network analysis

The network analysis was also employed to determine regulatory associations between the key miRNAs and hub KEGG pathways. In this network, miR-4492, miR-5193-3p and miR-641, which contributed more than other specifically expressed miRNAs exhibited 45, 44 and 44 KEGG pathways respectively (Table 6, Table S5). The most significantly KEGG pathway were MAPK signaling pathway, Ras signaling pathway, endocytosis and Rap1 signaling pathway, which involved in cell proliferation, growth, and differentiation (Table 7). The significantly complicated pathway associations of miRNAs with degree more than 30 are shown in Fig. 7.



Figure 1. Heatmap of the microarray hybridization result showed the differentially expressed miRNAs between HepG2/IR cells and its parental cells (HepG2 cells). Total RNA was extracted from both of two cell lines, miRNAs microarrays were performed as described in Materials and Methods, both cell lines were tested in triplicate.

Validation of miRNA array data

Based on their expression levels and fold changes, 4 downregulated miRNAs (miR-134-5p, miR-5195-3p, miR-641, miR-3935) and 10 upregulated miRNAs (miR-1231, miR-6726-5p, miR-3613-5p, miR-6779-5p, miR-7111-5p, miR-6870-5p, miR-6813-5p, miR-4492, miR-4505, miR-3180) were selected for validation by qRT-PCR. The results revealed a significant difference of the expression level of miR-4492, miR-3180, miR-134-5p, miR-5195-3p, miR-641 between the IR cells and control cells, which was in a manner consistent with the data obtained from microarray analysis (P<0.05) (Fig. 8). GO enrichment analysis revealed that these validated miRNAs were significantly enriched in biosynthetic process, cellular protein modification process, gene expression, small molecule metabolic process, catabolic process, cellular component assembly, post-translational protein modification (Table S4). The pathways were also significantly enriched in the KEGG analysis, and the most involved were cancer-related pathways, including the: Ras signaling pathway, Hippo signaling pathway, ErbB signaling pathway, other types of O-glycan biosynthesis, proteoglycans in cancer and cell adhesion molecules (CAMs) (Table S5).

Table	3.	Crucial	and	hub	target	genes	in	the	miRNA-target
networ	k (d	legree >	4)						

Crucial Target Gene	Description	Degree
CPLX2	Complexin-2	8
GRIN2B	Glutamate receptor ionotropic, NMDA 2B	8
KCNJ6	G protein-activated inward rectifier potassium channel 2	8
KSR2	Kinase suppressor of Ras 2	8
SYNGAP1	Ras/Rap GTPase-activating protein SynGAP	8
THRA	Thyroid hormone receptor alpha	8
AGAP2	Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 2	7
PTCH1	Protein patched homolog 1	7
SEMA4G	Semaphorin-4G	7
VAMP2	Vesicle-associated membrane protein 2	7
CDK6	Cyclin-dependent kinase 6	6
CRTC2	CREB-regulated transcription coactivator 2	6
PAK6	Serine/threonine-protein kinase PAK 6	6
PRKCA	Protein kinase C alpha type	6
ATP2B2	Plasma membrane calcium-transporting ATPase 2	5
CACNB3	Voltage-dependent L-type calcium channel subunit beta-3	5
FLNB	Filamin-B	5
PPP1R12B	Protein phosphatase 1 regulatory subunit 12B	5
SLC8A1	Sodium/calcium exchanger 1	5
VPS37D	Vacuolar protein sorting-associated protein 37D	5



Figure 2: Volcano plot of differentially expressed miRNA between HepG2/IR and HepG2 cells. The x-axis shows the Log2 fold-change in miRNA expression and y-axis shows the -Log10 of the p-value from HepG2/IR versus HepG2 cells. Labelled miRNAs have Log2 fold change greater than ISD from mean.



Figure 3. Significantly changed GO categories of predicted target genes of deregulated miRNAs between HepG2/IR and HepG2 cells. The y-axis shows GO category and the x-axis shows -lgP. The larger -lgP indicated a smaller P value. -lgP represent the negative logarithm of the P value. Blue bars indicate biological process (BP), red bars indicate cellular component (CC) and yellow bars indicate molecular function (MF).

Discussion

As the main anabolic hormone of the body, insulin regulates the metabolism of nutrients and promotes absorption of glucose from the blood into the cells. IR is the status when cells in the body, especially cells in the liver, fat and muscles don't respond well to insulin, and correspondingly the uptake and utilization of glucose decreases. At the whole organism level, IR will cause an impaired effect of insulin with lowering blood glucose, which may develop T2DM. To compensate for low blood glucose, the pancreas compensatory secretes excessive insulin to maintain blood sugar stability and to help glucose entering the cells. This excessive secretion leads to hyperinsulinemia in the body, which in turn activates hepatic lipogenesis and increased secretion of VLDL (hyperlipidemia) [20].

Table 4. Crucial miRNAs in the miRNA-GO network (degree >10)

miRNA	Degree
hsa-miR-4492	114
hsa-miR-641	114
hsa-miR-6779-5p	113
hsa-miR-6870-5p	113
hsa-miR-7111-5p	110
hsa-miR-3613-5p	109
hsa-miR-6780b-5p	108
hsa-miR-4505	106
hsa-miR-6846-5p	105
hsa-miR-6795-5p	104
hsa-miR-134-5p	101
hsa-miR-4793-5p	101
hsa-miR-6848-5p	101
hsa-miR-5195-3p	100
hsa-miR-1231	97
hsa-miR-6132	97
hsa-miR-6757-5p	97
hsa-miR-6813-5p	96
hsa-miR-6782-5p	92
hsa-miR-6085	91
hsa-miR-3935	81
hsa-miR-3937	74
hsa-miR-6805-5p	67
hsa-miR-6726-5p	63
hsa-miR-3180	59
hsa-miR-4649-5p	58
hsa-miR-4508	33
hsa-miR-4706	33
hsa-miR-7112-5p	33
hsa-miR-4467	29
hsa-miR-3621	20
hsa-miR-8072	16

Nonalcoholic fatty liver disease (NAFLD), as one of the most common liver disorders worldwide [21], had already been reported to have tight association with IR. Although NAFLD includes a disease spectrum, ranging from simple steatosis, liver cirrhosis to hepatocellular carcinoma (HCC) etc. [22,23] and the overall occurrence from NAFLD to HCC remains a rare complication [24,25]. IR had been reported to be associated with increased risk of several cancers, including HCC [26,27]. It had not only been related to tumorigenesis, but also been correlated to the poor prognosis of cancer patients [3-5]. Our previous studies also proved that IR could increase the invasiveness and MDR in the HCC cell line [6-9]. However, the molecular mechanism of therapeutic resistance caused by IR still remains unclear.

Our present study demonstrated that 27

miRNAs were consistently upregulated and 5 miRNAs were downregulated in the HepG2/IR cells upon triplicate tests. qRT-PCR was employed to verify the expression data of 14 differentially expressed miRNAs, which showed that the expression of 5 miRNAs were in consistent with the microarray data. The outcome of qRT-PCR validated that our result of microarray screening was reliable. Among these validated miRNAs, some had already been reported to be correlated with cancer. For instance, miR-134-5p had been reported as a tumor suppressing miRNA involving in several cancers. The anti-tumor mechanisms of miR-134-5p as the potential target of various lncRNAs which function as oncogene and it can also inhibit the expression of tumor suppressor genes by directly binding to the 3'UTR region. It was confirmed that impairing the expression of miR-134-5p can promote cell proliferation, inhibit cell apoptosis, accelerate cell migration, invasion, and induce EMT and moreover contribute to multidrug resistance such as cisplatin (targeting MBTD1), 5-FU (targeting KRAS) and paclitaxel (targeting TAB1) in several carcinoma cells including non-small-cell lung, gastric, nasopharyngeal, ovarian cancers and osteosarcoma [32-35,55,56]. Another microRNA reported was miR-641 which has been proved as a tumor suppressor; inhibiting proliferation, migration and invasion, as well as inducing apoptosis in lung cancer, cervical cancer and glioblastoma [36-38]. It was also confirmed that miR-641 contributes to erlotinib resistance in non-small-cell lung cancer by targeting NF1 and regulating ERK signaling [39]. However, little was known about the role of miR-641 in HCC. The only report about miR-641 and drug metabolism is that it acts as a direct post-transcriptional regulatory factor of CYP3A4, which is a member of the cytochrome P450 superfamily. As we all know, the cytochrome P450 proteins are monooxygenases in the hepatocytes that catalyze many reactions involved in drug metabolism, the enzyme also metabolizes some steroids and carcinogens as well [40]. Until now, the functions especially in tumorigenesis and drug resistance of other validated miRNAs such as miR-3180, miR-6726-5p, miR-7111-5p etc. have remained unclear. Our previous study has reported that insulin resistant HCC cells obtain ability of multidrug resistance such as cisplatin, 5-FU, vincristine, mitomycin [7]. In accordance with the researches mentioned above, miR-134-5p and miR-641 were down-regulated in insulin resistant HCC cells, thus suggesting that these known or unknown miRNAs might play a critical role in multidrug resistance of insulin resistant HCC cells especially miR-134-5p and miR-641. Further functional experiments will be conducted in our following study.

Table 5. Crucial GO category in the microRNA-GO network (degree >20)

BP COUNDER Display interaction compound metabolic proces 32 19770 BP COUNDERS biological proces 32 2.971-65 BP COUNDERS biological proces 32 2.971-65 BP COUNDERS transcription, DNA-temploide 31 4.151-77 BP COUNDERS transcription, DNA-temploide 31 0.141-87 BP COUNDERS transcription, DNA-temploide 30 3.951-81 BP COUNDERS macheosaccountraining compound catabolic proces 29 1.887-10 BP COUNDERS macheosaccountraining compound catabolic proces 29 0.043365 BP COUNDERS instructure system process 29 0.043365 BP COUNDERS instructure system process 28 0.0477611 BP COUNDERS instructure system process 27 3.864-35 BP COUNDERS process 26 0.0477611 BP COUNDERS process 26 0.0477611 <t< th=""><th>GO ID</th><th></th><th>GO (name)</th><th>Degree</th><th>P value</th></t<>	GO ID		GO (name)	Degree	P value
PP COUNDER biolographic proces S2 S27-43 PP COUNDES biolographic proces S2 Z274-46 PP COUNDES calabble proces S1 Z455-13 PP COUNDES calabble proces S1 Z455-13 PP COUNDES calabble proces S0 Z554-23 PP COUNDES anall macual empend calabble proces S0 Z554-23 PP COUNDES macroambeckar complex secold PP Z554-23 PP COUNDES macroambeckar complex secold PP Z554-23 PP COUNDES macroambeckar complex secold PP Z545-23 PP COUNDES macroambeckar complex secold PP Z545-23 PP COUNDES post macroambeckar complex secold PP Z545-23 PP COUNDES post macroambeckar complex secold PP Z545-23 PP COUNDES post macroambeckar complex secold Z645-27 PP COUNDES post macroambeckar	BP	GO:0034641	cellular nitrogen compound metabolic process	32	1.93E-70
N COUNDERSIM biological_process 32 2.45E-48 N COUNDEXOF cellular component assembly 31 4.351-72 N COUNDEXOF cellular protein madification process 30 5.251-83 N COUNDEXOF cellular protein madification process 30 5.251-83 N COUNDEXOF negloware to stress 30 5.251-33 N COUNDEXOF negloware to stress 30 5.251-33 N COUNDEXOF negloware stress 32 5.251-53 N COUNDEXOF negloware stress 32 5.251-53 N COUNDEXOF post-stressinging naturaliam throngh pravaition 32 5.251-53 N COUN	BP	GO:0009058	biosynthetic process	32	8.87E-43
BP COUNDEG calability crosses 91 2.4E-33 BY COUNDEG calability crospectal asembly 91 0.445-17 BY COUNDEG calability crospectal asembly 91 0.595-83 BY COUNDEG calability protein andification process 90 0.395-84 BY COUNDEG macheolase containing compound calability process 91 1.181-17 BY COUNDEG macheolase containing compound calability process 92 0.0333165 BY COUNDEG process 92 0.033165 BY COUNDEG process 93 0.034165 BY COUNDEG process 93 0.0	BP	GO:0008150	biological_process	32	2.79E-06
BF C.C.0022607 edilar component assembly 1 0.445617 BF C.C.002561 taxistription.DNA-remplated 30 0.5218-3 BF C.C.000464 cellular protein modification process 30 0.3218-3 BF C.C.0004650 response to stress 30 0.3486-27 BF C.C.0004650 response to stress 30 0.3486-27 BF C.C.0004651 protein complex assembly 20 0.8438-67 BF C.C.0004652 twoin complex assembly 20 0.8438-67 BF C.C.0004657 twoin complex assembly 20 0.8438-67 BF C.C.0004657 twoin complex assembly 20 0.0338-67 BF C.C.0004657 twoin complex assembly 20 0.0376-11 BF C.C.0004657 twoin complex assembly protein scaladial protein modification from complex assembly 20 0.0376-11 BF C.C.0004657 twoin protein modification from complex assembly 20 0.0376-11 BF C.C.0004670 protein modification from Complex assembly 26 2.418-5 BF C.C.0004674 protein modification from Complex assembly 26 2.518-5 BF C.C.0004674 protein modification	BP	GO:0009056	catabolic process	31	2.45E-18
BP COUNDON3 transcription.DNA-templated 91 0.444919 BP COUNDON3 ended prodoka modification process 93 2.21E-2 BP COUNDON3 mall molecule metabolic process 93 1.94E-1 BP COUNDON3 macromolecular complex seemshy 93 1.94E-1 BP COUNDON31 provendecular complex seemshy 94 0.003716 BP COUNDON32 endedname 94 0.003716 BP COUNDON32 immane system process 93 0.003716 BP COUNDON32 INA metabolic process 93 0.003716 BP COUNDON24 onterbalant frame system proces 93 0.00751 BP COUNDON24 onterbalant frame system proces 94 0.001711 BP COUNDON24 onterbalant frame system proces 94 0.001711 BP COUNDON24 respression metabolic proces 94 0.001711 BP COUNDON24 respression metabolic proces 94 0.001711	BP	GO:0022607	cellular component assembly	31	4.15E-17
BF COUND144 calibrar protein modification process 90 SPSI-38 BF COUND1450 response to stress 90 SPSI-38 BF COUND1450 nepome to stress 90 SPSI-38 BF COUND1501 netostress 90 SPSI-38 BF COUND1502 vested-mediated transport 90 SPSI-38 BF COUND1502 vested-mediated transport 20 0.0033165 BF COUND1502 vested-mediated transport 20 0.0033165 BF COUND1407 gene expression 20 <td>BP</td> <td>GO:0006351</td> <td>transcription, DNA-templated</td> <td>31</td> <td>0.0449519</td>	BP	GO:0006351	transcription, DNA-templated	31	0.0449519
PF COUNTRY Sale of Country Sale of Country PF COUNTRY Sale of Country	BP	GO:0006464	cellular protein modification process	30	5.95E-38
Bit COUND199 repuese oriens 9 1.981-11 Bit COUND195 macromolecular complex asembly 29 1.991-10 Bit COUND192 veiale-machalact interport 29 0.0433165 Bit COUND192 veiale-machalact interport 29 0.0433165 Bit COUND192 veiale-machalact interport 29 0.0433165 Bit COUND192 veiale-machalact interport 28 0.075611 Bit COUND1947 perc-opression 27 3.001-33 Bit COUND1447 perc-opression 28 0.0275-23 Bit COUND1447 veial-process 28 0.02175-23 Bit COUND1447 veial-process 28 0.02175-23 Bit COUND1437 veial-process 28 0.02175-23 Bit COUND1437 veial-process 28 0.02175-23 Bit COUND1437 reprocess 28 0.02175-23 Bit COUND1437	BP	GO:0044281	small molecule metabolic process	30	2.21E-23
BitCOUNTAGESPS1.988-1-11BitCOUNTAGESprotein complex assembly293.485-07BitCOUNTAGESprotein complex assembly290.485-07BitCOUNTAGESprotein complex assembly280.0073611BitCOUNTAGESprotein complex assembly280.0073611BitCOUNTAGESprotein complex assembly280.0073611BitCOUNTAGESprotein complex assembly280.0073611BitCOUNTAGESprotein complex assembly280.0073611BitCOUNTAGESprotein complex assembly assembly260.0073611BitCOUNTAGESprotein complex assembly assembly260.0175-26BitCOUNTAGESprotein complex assembly assembly assembly260.0175-26BitCOUNTAGESprotein complex assembly assembly260.0175-26BitCOUNTAGESprotein complex assembly assembly260.0175-26BitCOUNTAGEprotein complex assembly260.0175-26BitCOUNTAGEprotein complex assembl	BP	GO:0006950	response to stress	30	3.49E-09
81820.0008300macromolecular complex assembly291.919-10820.00015192vesicle-mediated transport290.00433165840.0003205mone system process282.978-66840.0003205pel death282.978-66840.0003210edi death282.978-66840.0003411egne expression273.608-33840.0004467egne expression278.968-20840.0004467cellular protein metholic process206.948-37840.0004467vestorepoin strataling palway265.188-12840.0004467vestorepoin strataling palway265.188-12840.0004072viral process260.9178-03840.0004072repulsion of nall CTP-se metalated signal transduction261.978-03840.0004074repulsion of nall CTP-se metalated signal transduction261.978-03840.0007950repulsion from RNA polymense II promoter260.9078-03840.0007950repulsion from RNA polymense II promoter250.9078-03850.0007950repulsion from RNA polymense II promoter260.9078-0386<	BP	GO:0034655	nucleobase-containing compound catabolic process	29	1.98E-11
BitCO0001401protein complex asembly290.481-07BitCO000257immune system process282.047-06BitCO000259DNA metabolic process280.0073611BitCO000259DNA metabolic process280.0073611BitCO000259DNA metabolic process280.0073611BitCO000259DNA metabolic process271.571-36BitCO0004401symbols, encompassing mutualism through parasitism271.571-36BitCO0004507protestransfalling pathway266.941-37BitCO000507protestransfalling protein medification261.315-09BitCO000507rendersan enganization261.315-09BitCO000507rendersan enganization260.0072-63BitCO000507rendersan enganization260.0072-63BitCO000507rendersan enganization260.0072-63BitCO000507rendersan enganization260.0052-03BitCO0007286synaptic transmission210.009643BitCO0007286synaptic transmission230.000274-13BitCO0007286synaptic transmission230.000274-13BitCO0007286synaptic transmission230.000274-13BitCO0007286synaptic transmission230.000274-13BitCO0007286synaptic transmission230.000274-13BitCO000728	BP	GO:0065003	macromolecular complex assembly	29	1.19E-10
IPCO.0015192veicle-mediated transport290.043165IPCO.0008219cell death282.977-66IPCO.0008219cell death282.977-66IPCO.001047genc expression273.061-35IPCO.001447genc expression278.987-20IPCO.001497cellular protein metabolic proces278.987-20IPCO.001497cellular protein metabolic proces282.417-26IPCO.001602vial proces262.417-26IPCO.001602vial proces262.417-26IPCO.001602regulation of small GP as metabolic proces261.877-16IPCO.001602regulation of small GP as metabolic proces261.877-16IPCO.001504regulation of small GP as metabolic proces260.0774-18IPCO.001592homeostatic proces260.0757-18IPCO.001592homeostatic proces250.877-65IPCO.001590explation of small GP as metabolic proces250.887-66IPCO.001670RNA metabolic proces210.00234IPCO.001670RNA metabolic proces240.0098931IPCO.001670RNA metabolic proces240.0908931IPCO.001670RNA metabolic proces240.0908931IPCO.001670splating pathway240.0908931IPCO.001670splating pathway24 <td>BP</td> <td>GO:0006461</td> <td>protein complex assembly</td> <td>29</td> <td>3.48E-07</td>	BP	GO:0006461	protein complex assembly	29	3.48E-07
IP BCO-00027/eimmune system process282.04E-06BPCO-0000279DNA metabolic process380.0075/h11BPCO-000407gene expression373.06F-55BPCO-0004403symbiosic, encomposing mutalism through parsaitism373.06F-55BPCO-0004403symbiosic, encomposing mutalism through parsaitism373.06F-55BPCO-0004403enumeraphilis TKK recepter signaling pathway664.25F-17BPCO-0004567post-transditional protein modification664.25F-17BPCO-000567replathon of small GTPase mediated signal transduction661.35F-10BPCO-000576replathon of small GTPase mediated signal transduction660.07F-16BPCO-000567replathon of small GTPase mediated signal transduction660.07F-16BPCO-000578extraoclubic noces750.000274BPCO-000579extraoclubic proces250.000274BPCO-000578extraoclubic proces250.000274BPCO-000728extraoclubic proces240.000162BPCO-000710extraoclubic proces240.000162BPCO-000710extraoclubic proces240.000162BPCO-000710extraoclubic proces240.000162BPCO-000710extraoclubic proces240.000162BPCO-000710extraoclubic proces240.000162BPCO-00077	BP	GO:0016192	vesicle-mediated transport	29	0.0433165
BP GO-00082/9 col.dom 28 2470-06 BP GO-001047 gene expression 360-35 BP GO-001427 collablar protein metabolic process 27 8,96-30 BP GO-0014267 collablar protein metabolic process 26 4,315-36 BP GO-0014267 relaboration motification 26 4,315-17 BP GO-001602 metarine organization 26 4,315-17 BP GO-0001602 relaboration initiation from INA polymerase Il promoter 26 5,316-12 BP GO-0001605 regulation of small GT base mediated signal transduction 26 0,377-18 BP GO-0001605 transcription initiation from INA polymerase Il promoter 26 0,070-94 BP GO-0001605 transcription initiation from INA polymerase Il promoter 26 0,072-14-8 BP GO-000167 transcription initiation from INA polymerase Il promoter 26 0,072-14-8 BP GO-000170 transcription initiation from INA polymerase Il promoter 26 0,072-14-8 BP GO-000170 transcription initiation from INA polymerase Il promoter 26 0,072-14-8 BP GO-000170 transcription initiation from INA polymerase II promoter 26 0,	BP	GO:0002376	immune system process	28	2.04E-06
BP COA0006299 DNA metabolic process 28 0.0075011 BP COA0044403 symbiosis, encomposing mutualism through parasitism 27 1.871-26 BP COA004507 cellular protein metabolic process 27 8.961-20 BP COA004501 neurotrophin TRK neceptor signaling pathway 26 6.941-57 BP COA004502 rule process 26 2.111-26 BP COA004507 rule process 26 2.111-26 BP COA00507 rule-rule signaling 26 1.318-10 BP COA00507 rule-rule signaling 26 0.571-56 BP COA00507 transcription initiation from RNA polymerase Il promoter 26 0.871-63 BP COA00507 transcription initiation from RNA polymerase Il promoter 26 0.871-63 BP COA00507 transcription initiation from RNA polymerase Il promoter 25 5.51-14 BP COA00507 rule rule rule rule rule rule rule rule	BP	GO:0008219	cell death	28	2.97E-06
BP COM01447 gene expression 27 3.401-35 BP COM04267 cellular protein metabolic process 27 8.965-201 BP COM04267 cellular protein metabolic process 26 6.941-57 BP COM04027 viral process 26 2.412-66 BP COM05105 repairation 26 1.312-19 BP COM05105 repairation 26 1.312-19 BP COM05105 repairation initiation from RNA polymerase I promoter 26 0.578-16 BP COM05105 transcription initiation from RNA polymerase I promoter 26 0.050233 BP COM0505 transcription initiation from RNA polymerase I promoter 26 0.050233 BP COM0505 transcription initiation from RNA polymerase I promoter 26 0.050233 BP COM0505 transcription initiation from RNA polymerase I promoter 25 0.578-143 BP COM0507 RNA metabolic process 20 0.057933 BP COM0507 repairation initiation from RNA polymerase 20 0.00021 BP COM0507 repairation process 23 0.858-14 BP COM0507 repairation stranscription repairation 24	BP	GO:0006259	DNA metabolic process	28	0.0073611
IP COUND4405 cymbiosis, encompassing mutualism through parasitism Z 1.875-26 BP COUND4057 collular protein metabolic process 26 6.415-27 BP COUND4057 pest-translational protein modification 26 4.236-17 BP COUND4057 pest-translational protein modification 26 1.13E-09 BP COUND4057 regulation of small GTPs mediated signal transduction 26 1.13E-09 BP COUND5057 regulation of small GTPs mediated signal transduction 26 0.0756-05 BP COUND5056 transcription initiation from RNA polymerase. IP promoter 26 0.0756-123 BP COUND5056 blood couglation 25 5.575-14 BP COUND506 blood couglation 25 0.000274 BP COUND507 ell motility 25 0.000274 BP COUND507 ell motility 25 0.000274 BP COUND507 ell motility 26 0.00021 BP COUND507 ell motility	BP	GO:0010467	gene expression	27	3.60E-35
BP COU04207 cellular protein metabolic process Cellular procesproces	BP	GO:0044403	symbiosis, encompassing mutualism through parasitism	27	1.57E-26
BP COU049011 neurotrophin TRK receiver signaling pathway 26 4.24F-26 BP COU049024 read process 26 4.24F-26 BP COU0491024 membrane organization 26 4.13E-04 BP COU051056 regulation of small GTB-se mediated signal transduction 26 1.13E-04 BP COU05070 cell-cell signaling 26 0.17E-05 BP COU05070 regulation of small GTB-se mediated signal transduction 26 0.0796-05 BP COU05070 regulation of small GTB-se mediated signal transduction 26 0.0796-05 BP COU05070 regulation of semall GTB-se mediated signal transduction 26 0.0796-05 BP COU05070 regulation of semall GTB-se mediated signal transduction 26 0.0796-05 BP COU05070 regulation from RNA polymerase II pronotor 25 0.0702-05 BP COU05070 regulation from RNA polymerase II pronotor 25 0.00027-05 BP COU05070 regulation from RNA metabolic process 25 0.00027-05 BP COU05070 regulation regulation gamiway 26 0.00016-02 BP COU05070 regulation regulation gamiway 26 0.00016-02 <tr< td=""><td>BP</td><td>GO:0044267</td><td>cellular protein metabolic process</td><td>27</td><td>8.96E-20</td></tr<>	BP	GO:0044267	cellular protein metabolic process	27	8.96E-20
BP COUNTIONS 26 24.81-26 BP COUNSAST post-translational protein modification 26 4.381-17 BP COUNT267 cell-cell signaling 26 1.181-09 BP COUNT267 cell-cell signaling 26 1.181-09 BP COUNT267 cell-cell signaling 26 1.072-05 BP COUNT267 transcription initiation from RNA polymerase II promoter 26 0.0079643 BP COUNT268 synaptic transmission 26 0.0079643 BP COUNT268 synaptic transmission 25 0.0002734 BP COUNT270 RNA metabolic proces 24 0.0001162 BP COUNT273 neprotoxi s	BP	GO:0048011	neurotrophin TRK receptor signaling pathway	26	6.94E-37
BP GA00033867 post-translational protein modification 26 4.284-7 BP GA0007247 cell-cell signaling 26 1.181-00 BP GA000847 transcription initiation from RNA polymerase II promoter 26 0.57E-05 BP GA0008467 transcription initiation from RNA polymerase II promoter 26 0.007943 BP GA0007268 synaptic transmission 26 0.0064203 BP GA0007268 synaptic transmission 25 6.57E-18 BP GA0007268 synaptic transmission 25 0.000724 BP GA0007786 synaptic transmission 25 0.000724 BP GA000700 cytosketon organization 25 0.00071 BP GA000701 cytosketon organization 25 0.00071 BP GA000710 cytosketon organization 24 0.00162 BP GA000710 cytosketon organization 24 0.00074 BP GA000710 cytosketon organization 24 0.00072 <	BP	GO:0016032	viral process	26	2.41E-26
B GO.006/024 production membrane organization 2 5.88-2 BF GO.0007267 cell-cell signaling 26 1.138-09 BF GO.0007267 cell-cell signaling 26 1.078-05 BF GO.0007367 transcription initiation from RNA polymerase II promoter 26 0.0079643 BF GO.0007586 biolod cosquitation 26 0.0079643 BF GO.0007586 biolod cosquitation 25 0.5578-14 BF GO.0007586 synaptic transmission 25 0.0002734 BF GO.0016070 RNA metabolic process 25 0.0002734 BF GO.0016071 mRAM metabolic process 24 0.0001162 BF GO.0016071 mRNA metabolic process 24 0.000142 BF GO.00016071 mRNA metabolic process 24 0.000142 BF GO.000790 suptotic signaling pathway 23 1.272-14 BF GO.000790 suptotic signaling pathway 23 2.278-14	BP	GO:0043687	post-translational protein modification	26	4 23E-17
model cell-cell signaling path and the second seco	BP	GO:0040007	membrane organization	26	5.18E-12
action Construct Construct Construct BP CO005106 regulation of small CTP ase mediated signal transduction 26 5.77E-05 BP CO0005292 homeostatic process 26 0.007964 BP CO000756 blood coggulation 26 0.005103 BP CO000756 blood coggulation 25 5.75E-14 BP CO000756 synaptic transmission 25 0.0002734 BP CO000700 rytoskic process 25 0.0002734 BP CO000701 rytoskicton organization 25 0.0002734 BP CO000701 rytoskicton organization 24 0.005903 BP CO000701 rytoskicton organization 24 0.0084890 BP CO000701 arytos system development 24 0.0092641 BP CO000739 narrous system development 23 1.22E-14 BP CO000773 enderbablic process 23 2.21E-10 BP CO0000713 epidermala	BP	GO:0001024 CO:0007267	coll coll signaling	20	1 13E 09
Instruction Columnation Columnation <thcolumnation< th=""> <thcolumnation< th=""></thcolumnation<></thcolumnation<>	BP	GO:0007207	regulation of small CTPase modiated signal transduction	20	1.07E 05
International content of a production of a content of a production Description Description BP CO.0002592 homeostatic process 26 0.0351203 BP CO.0007596 blood cogatilation 25 5.551-14 BP CO.0007596 blood cogatilation 25 3.881-66 BP CO.0007506 synaptic transmission 25 0.0002734 BP CO.0007010 cytoskelon organization 25 0.0002734 BP CO.0007010 cytoskelon organization 26 0.0005913 BP CO.0007010 cytoskelon organization 24 0.0005913 BP CO.0007910 apoptotic signaling pathway 24 0.0002401 BP CO.000790 netrotory signaling pathway 23 1.461-26 BP CO.0007173 epidemal growth factor receptor signaling pathway 23 2.21E-10 BP CO.000278 nitrot conto with factor receptor signaling pathway 23 2.21E-10 BP CO.000278 insterin receptor signaling pathway 23 <t< td=""><td>BP</td><td>GO:0001050 CO:0006367</td><td>transcription initiation from RNA polymoraca II promotor</td><td>20</td><td>5.57E.05</td></t<>	BP	GO:0001050 CO:0006367	transcription initiation from RNA polymoraca II promotor	20	5.57E.05
International process International procesprot process International process </td <td>BP</td> <td>GO:0000507 CO:0042592</td> <td>homoostatic process</td> <td>20</td> <td>0.0079643</td>	BP	GO:0000507 CO:0042592	homoostatic process	20	0.0079643
Int Colonom Co	BP	GO:0042392	ovtracellular matrix organization	20	0.007.9043
Br GC0.007298 synaptic transmission 20 0.715-10 BP GC0.007298 synaptic transmission 25 3.58E-06 BP GC0.0045087 innate immune response 25 0.0002734 BP GC0.007010 cytoskelton organization 25 0.000274 BP GC0.007010 cytoskelton organization 25 0.000127 BP GC0.000711 axon guidance 24 0.000162 BP GC0.000711 axon guidance 24 0.009261 BP GC0.0007139 apoptotic signaling pathway 24 0.009261 BP GC0.0008905 E-ceysolin creeptor signaling pathway 23 1.46E-26 BP GC0.000273 epidermal growth factor receptor signaling pathway 23 2.21E-10 BP GC0.000278 mitotic cell cycle 23 2.21E-10 BP GC0.000278 mitotic cell cycle 23 2.21E-10 BP GC0.000278 mitotic cell cycle 23 2.21E-06 BP	BP	GO:0000196	blood coogulation	20	6 77E 18
B COUNTRY COUNTRY COUNTRY BF COUNTRY INAM metabolic process 25 3.88E-06 BF COUNTRY Innate immune response 25 0.0002734 BF COUNTRY Innate immune response 25 0.000421 BF COUNTRY Innate immune response 25 0.000421 BF COUNTRY Innate immune response 24 0.0001162 BF COUNTRY axon guidance 24 0.0001162 BF COUNTRY axon guidance 24 0.0002641 BF COUNTRY nervous system development 23 1.72E-14 BF COUNTRY e-pielernal growth factor receptor signaling pathway 23 1.72E-14 BF COUNTRY e-pielernal growth factor receptor signaling pathway 23 2.73E-06 BF COUNTRY e-pielernal growth factor receptor signaling pathway 23 0.002751 BF COUNTRY patelet activation 23 2.73E-06 BF COUNTRY	BD	GO:0007390	gynantic transmission	25	5.55E 14
BI GC00140070 INVA Inclusion process 2.0 0.00012734 BP GC001408087 cill motility 25 0.0002734 BP GC000140071 moRNA metabolic process 24 0.4911-000 BP GC0007101 cytoskeleton organization 24 0.0001162 BP GC0007111 axon guidance 24 0.0001204 BP GC0000790 apoptotic signaling pathway 24 0.000241 BP GC0000790 nervous system development 24 0.009261 BP GC0000203 ejidermal growth factor receptor signaling pathway 23 1.446-26 BP GC0000203 gidycosmineglycan metabolic process 23 2.211-01 BP GC0000278 minotic cell cycle 23 2.211-01 BP GC0000278 minotic cell cycle 23 2.211-01 BP GC0000286 insulin receptor signaling pathway 23 2.011-06 BP GC00001921 cytokine-mediated signaling pathway 23 3.921-06	BD	GO.0007208	PNA metabolic process	25	2 88E 06
bit COMPARATION COMPARATION COMPARATION BP COMMARTO Col Montal Influer Inspirate 25 0.0005913 BP COMMARTO CS 0.0005913 BP COMMARTO AMENA metabolic process 24 0.0001162 BP COMMORTON axon guidance 24 0.00034909 BP COMMORTON papototic signaling pathway 24 0.00392062 BP COMMORTON system development 23 1.72E-14 BP COMMORTON epidermal growth factor receptor signaling pathway 23 1.72E-14 BP COMMORTON epidermal growth factor receptor signaling pathway 23 2.73E-07 BP COMMORTON glycosaminoglycan metabolic process 23 2.73E-07 BP COMMORTON glycosaminoglycan metabolic process 23 2.73E-07 BP COMMORTON glycosaminoglycan metabolic process 23 2.03E-06 BP COMMORTON glycosaminoglycan metabolic process 23 2.03E-06 B		GO.0010070	innoto immuno rosponos	25	0.0002724
br COUMERATION COUMERATION COUMERATION BF GOUDOTIOL cytoskeleton organization 25 0.0009913 BP GOUDOTIOL cytoskeleton organization 24 0.0001162 BP GOUDOTALL axon guidance 24 0.0009741 BP GOUDOTAPD apoptotic signaling pathway 24 0.009261 BP GOUDOTAPD apoptotic signaling pathway 23 1.46E-26 BP GOUDOTAPD epidermal growth factor receptor signaling pathway 23 1.72E-14 BP GOUDO228 glycosaminoglycan metabolic process 23 2.73E-07 BP GOUD0228 mitotic cell cycle 23 2.73E-07 BP GOUD0228 mitotic cell cycle 23 2.73E-07 BP GOUD0228 mitotic cell cycle 23 3.73E-07 BP GOUD0221 cytokine-mediated signaling pathway 23 2.61E-06 BP GOUD02521 cytokine-mediated signaling pathway 22 3.00E-06 BP	DF	GO:0045087	annate immune response	25	0.0002754
br GC0000100 Clymsketecht organization 25 0.0079915 BP GC0016071 mRNA metabolic process 24 0.001162 BP GC0007399 apoptotic signaling pathway 24 0.009264 BP GC0007399 nervous system development 24 0.009264 BP GC00007390 sulfur compound metabolic process 24 0.009264 BP GC0000713 epidermal growth factor receptor signaling pathway 23 1.72E-14 BP GC0000278 mitotic cell cycle 23 2.78E-08 BP GC0000278 mitotic cell cycle 23 2.61E-06 BP GC0000278 insulin receptor signaling pathway 23 0.00327518 BP GC0001921 cytokine-mediated signaling pathway 23 2.61E-06 BP GC0001921 cytokine-mediated signaling pathway 22 3.49E-09 BP GC0001921 cytokine-mediated signaling pathway 22 0.0046663 BP GC0001921 cytokine-mediated signaling pathway	DF PD	GO:0046670	cell motility	25	0.000421
br GC0000711 mRXAr MetaBolic process 24 349E-199 BP GC0007110 axon guidance 24 0.0001162 BP GC0007390 apoptotic signaling pathway 24 0.009261 BP GC0006790 suffur compound metabolic process 24 0.00392062 BP GC0006790 suffur compound metabolic process 23 1.46E-26 BP GC0000713 epidermal growth factor receptor signaling pathway 23 2.71E-14 BP GC0000278 mitotic cell cycle 23 2.73E-08 BP GC0000278 mitotic cell cycle 23 0.0327518 BP GC00008286 insulin receptor signaling pathway 23 0.0327518 BP GC0008231 fibroblast growth factor receptor signaling pathway 23 0.0327518 BP GC0008254 chromatin organization 22 3.30E-06 BP GC00004330 cell junction organization 22 0.0046663 BP GC0000535 chromatin organization 22 <td< td=""><td>DF</td><td>GO:0007010</td><td>cytoskeleton organization</td><td>25</td><td>0.0095915</td></td<>	DF	GO:0007010	cytoskeleton organization	25	0.0095915
br CO:00/11 avon gnitance 24 0.001162 BP GO:007710 apoptitic signaling pathway 24 0.0082062 BP GO:0007399 nervous system development 24 0.0082062 BP GO:0007390 sulfar compound metabolic process 24 0.0392062 BP GO:0007173 epidermal growth factor receptor signaling pathway 23 1.72E-14 BP GO:0000278 mitotic cell cycle 23 2.73E-08 BP GO:0000278 mitotic cell cycle 23 3.73E-07 BP GO:000278 mitotic cell cycle 23 0.0327518 BP GO:0002866 insulin receptor signaling pathway 23 0.0327518 BP GO:0008243 fibroblast growth factor receptor signaling pathway 22 3.30E-06 BP GO:0008243 fibroblast growth factor receptor signaling pathway 22 0.004663 BP GO:0008543 fibroblast growth factor receptor signaling pathway 22 0.014663 BP GO:0006325 chromatin or	DF	GO:00160/1	mkinA metabolic process	24	3.49E-09
bPCO.007.190apoptotic signaling pathway240.0084969BPGO.007390nervous system development240.0032061BPGO.008095Fc-epsilon receptor signaling pathway231.46E-26BPGO.0007173epidermal growth factor receptor signaling pathway231.72E-14BPGO.000203glycosaminoglycan metabolic process232.21E-10BPGO.000206pattet activation233.73E-07BPGO.000278mitotic cell cycle233.73E-07BPGO.0002866insulin receptor signaling pathway230.0327518BPGO.0008543fibroblast growth factor receptor signaling pathway230.0327518BPGO.0008543fibroblast growth factor receptor signaling pathway223.34E-07BPGO.0008543fibroblast growth factor receptor signaling pathway220.0027518BPGO.0008543fibroblast growth factor receptor signaling pathway220.004663BPGO.0004530cell junction organization220.004663BPGO.000632chromatin organization220.004663BPGO.0008096Fc-gamma receptor signaling pathway211.01E-13BPGO.0008295chromatin organization210.0024663BPGO.0008296celluar matrix disassembly210.0024663BPGO.0008296fc-gamma receptor signaling pathway2162:Fo7BPGO.0008296fc-gamma receptor s	DP	GO:0007411	axon guidance	24	0.0001162
BP CO.000/399 nervous system development 24 0.009241 BP GO.0006790 sulfur compound metabolic process 24 0.0392062 BP GO.0007173 epidermal growth factor receptor signaling pathway 23 1.72E-14 BP GO.000278 mitotic cell cycle 23 2.21E-10 BP GO.000278 mitotic cell cycle 23 2.73E-08 BP GO.000278 mitotic cell cycle 23 0.0327518 BP GO.0002886 insulin receptor signaling pathway 23 0.0327518 BP GO.0008286 insulin receptor signaling pathway 23 0.0327518 BP GO.0008281 fibroblast growth factor receptor signaling pathway 22 3.49E-09 BP GO.0004142 toll-like receptor 4 signaling pathway 22 0.0406633 BP GO.0004313 cell-roten or signaling pathway involved in phagocytosis 21 1.01E-13 BP GO.0004312 genemation of precursor metabolites and energy 22 0.04400089 BP GO.00	BP	GO:0097190	apoptotic signaling pathway	24	0.0084989
BP CO000590 Suffir compound metabolic process 24 0.009202 BP GO0038005 Fc-epilon receptor signaling pathway 23 1.72E-14 BP GO000278 glycosaminoglycan metabolic process 23 2.21E-10 BP GO000278 mitotic cell cycle 23 2.73E-08 BP GO000278 mitotic cell cycle 23 2.61E-06 BP GO0005846 insulin receptor signaling pathway 23 0.0327518 BP GO0005843 fibroblast growth factor receptor signaling pathway 22 2.40E-06 BP GO0005843 fibroblast growth factor receptor signaling pathway 22 2.40E-06 BP GO0005843 fibroblast growth factor receptor signaling pathway 22 2.23E-08 BP GO000352 chonatin organization 22 0.046663 BP GO0003261 ethracellular matrix disassembly 22 0.0460089 BP GO0003806 Fc-gamma receptor signaling pathway involved in phagocytosis 21 1.01E-13 BP GO0008	BP	GO:0007399	nervous system development	24	0.0092641
DP CO003895 Freepsion receptor signaling pathway 25 1.46E-26 BP GO007173 epidermal growth factor receptor signaling pathway 23 2.21E-10 BP GO0000278 mitotic cell cycle 23 2.73E-08 BP GO0001273 mitotic cell cycle 23 2.73E-08 BP GO0001221 cytokine-mediated signaling pathway 23 0.0327518 BP GO0003168 platelet activation 23 0.0327518 BP GO00031412 toll-like receptor signaling pathway 22 3.49E-09 BP GO00034142 toll-like receptor signaling pathway 22 3.30E-06 BP GO000355 chromatin organization 22 0.034599 BP GO000691 generation of precursor metabolites and energy 22 0.0346663 BP GO0005261 toll-like receptor signaling pathway involved in phagocytosis 21 1.01E-13 BP GO0005241 toll-like receptor signaling pathway 21 0.0014663 BP GO0005241 t	BP	GO:0006790	sulfur compound metabolic process	24	0.0392062
BP GC000071/3 epidermal growin factor receptor signaling pathway 2.5 1.72-14 BP GO0030203 glycosaminoglycan metabolic process 23 2.21E-10 BP GO000278 mitotic cell cycle 23 2.73E-08 BP GO000286 insulin receptor signaling pathway 23 2.61E-06 BP GO000286 insulin receptor signaling pathway 23 2.61E-06 BP GO000278 ribroblast growth factor receptor signaling pathway 22 3.49E-09 BP GO0008543 fibroblast growth factor receptor signaling pathway 22 2.22E-08 BP GO0003203 cell junction organization 22 0.004663 BP GO0000251 chromatin organization 22 0.004663 BP GO00002617 extracellular matrix disassembly 22 0.004663 BP GO0003026 promatin organization 22 0.004663 BP GO0003096 Fc-gamma receptor signaling pathway involved in phagocytosis 21 1.01E-13 BP GO0000224 </td <td>BP</td> <td>GO:0038095</td> <td>Fc-epsilon receptor signaling pathway</td> <td>23</td> <td>1.46E-26</td>	BP	GO:0038095	Fc-epsilon receptor signaling pathway	23	1.46E-26
BPGC0000278gitycosaninogiycan metabolic process2.52.52.11e-10BPGC0000278mitotic cell cycle232.73E-08BPGC00002866insulin receptor signaling pathway230.0327518BPGC0008543fibroblast growth factor receptor signaling pathway230.0327518BPGC0008543fibroblast growth factor receptor signaling pathway223.49E-09BPGC0003142toll-like receptor 4 signaling pathway220.00327518BPGC00034142toll-like receptor 4 signaling pathway220.004663BPGC00022617extracellular matrix disassembly220.00138599BPGC0006091generation of precursor metabolites and energy220.01460089BPGC00034162toll-like receptor 9 signaling pathway involved in phagocytosis211.01E-13BPGC0002244toll-like receptor 9 signaling pathway210.0046663BPGC0006928cellular component movement210.001544BPGC000664phosphatidylinositol-mediated signaling210.001544BPGC0000684G2/M transition of mitotic cell cycle301.17E-15CCGC000575cellular_component301.17E-15CCGC0005654nucleoplasm301.17E-15CCGC0005654nucleoplasm301.13E-13CCGC0005654nucleoplasm301.13E-13CCGC0003676indrowplasm32<	BP	GO:000/1/3	epidermal growth factor receptor signaling pathway	23	1./2E-14
BP CO.0002/7s Initiatic cell cycle 23 2.7.31-18 BP CO.0003168 platelet activation 23 3.731-07 BP CO.0008286 insulin receptor signaling pathway 23 0.0327518 BP CO.0008243 fibroblast growth factor receptor signaling pathway 22 3.391-09 BP CO.0008430 cell junction organization 22 3.301-06 BP CO.0006325 chromatin organization 22 0.0046663 BP CO.0008260 recreating pathway involved in phagocytosis 21 1.011-3 BP CO.0006091 generation of precursor metabolites and energy 22 0.046663 BP CO.0003162 toll-like receptor signaling pathway involved in phagocytosis 21 1.011-13 BP CO.0002244 toll-like receptor signaling pathway 21 6.222-07 BP CO.0006925 relawar metapointed signaling 21 1.011-3 BP CO.0006224 toll-like receptor signaling pathway 21 0.0001544 BP CO.000	BP	GO:0030203	giycosaminogiycan metabolic process	23	2.21E-10
BPGO:0003108plateit activation233.7.3E-1/BPGO:0008286insulin receptor signaling pathway232.61E-06BPGO:0019221cytokine-mediated signaling pathway223.49E-09BPGO:0034142toll-like receptor 4 signaling pathway222.23E-08BPGO:0034330cell junction organization220.0046663BPGO:0022617extracellular matrix disassembly220.0046663BPGO:0022617extracellular matrix disassembly220.0046089BPGO:0034162toll-like receptor 9 signaling pathway involved in phagocytosis211.01E-13BPGO:0034162toll-like receptor 9 signaling pathway216.22E-07BPGO:002261toll-like receptor 9 signaling pathway216.22E-07BPGO:002261toll-like receptor 9 signaling pathway211.01E-13BPGO:002261toll-like receptor 9 signaling pathway216.22E-07BPGO:002261toll-like receptor 9 signaling pathway216.22E-07BPGO:0002264toll-like receptor signaling pathway210.001544BPGO:0006928cellular component movement219.77E-05BPGO:000575cellular_component301.17E-15CCGO:0005864protein complex301.03E-13CCGO:0005875retion of mitotic cell cycle301.03E-13CCGO:0005815microtubule organizing center26<	BP	GO:0000278	mitotic cell cycle	23	2.73E-08
BPGC:0008286insulin receiptor signaling pathway232.61E-06BPGC:0019221cytokine-mediated signaling pathway230.0327518BPGC:0008543fibroblast growth factor receiptor signaling pathway223.49E-09BPGC:0034142toll-like receiptor 4 signaling pathway222.23E-08BPGC:0006325chromatin organization220.0046663BPGC:0006325chromatin organization220.046663BPGC:0006325chromatin of precursor metabolites and energy220.0466089BPGC:0008091generation of precursor metabolites and energy220.0460089BPGC:00038096Fc-gamma receiptor signaling pathway involved in phagocytosis211.01E-13BPGC:0002241toll-like receiptor signaling pathway216.22E-07BPGC:00048015phosphatidylinositol-mediated signaling210.000154BPGC:0006928cellular component movement219.77E-05BPGC:000575cellular_component movement210.000154BPGC:000575cellular_component301.17E-15CCGC:0005824protein complex301.17E-15CCGC:0005854nucleoplasm301.03E-13CCGC:0005815microtubule organizing center260.0031329CCGC:0005815microtubule organizing center329.58E-29MFGC:0003674molecular_function32	BP	GO:0030168	platelet activation	23	3.73E-07
BPGC:0019221cytokine-mediated signaling pathway230.0327518BPGC:0008543fibroblast growth factor receptor signaling pathway223.49E-09BPGC:0034130cell junction organization223.30E-06BPGC:0006325chromatin organization220.0046663BPGC:002617extracellular matrix disassembly220.0138599BPGC:0038096Fc-gamma receptor signaling pathway involved in phagocytosis211.01E-13BPGC:0038096Fc-gamma receptor signaling pathway211.01E-09BPGC:0002244toll-like receptor 9 signaling pathway216.22E-07BPGC:0006928cellular component movement210.000154BPGC:0006644phospholipid metabolic process210.0001544BPGC:000575cellular component220.0424742CCGC:0005829cytosol301.17E-15CCGC:000584moteoplasm301.17E-15CCGC:0005815microtubule organizing center260.0031329CCGC:0005815microtubule organizing center260.0031329CFGC:0005815microtubule organizing center260.0031329MFGC:0005674molecular_function325.38E-29	BP	GO:0008286	insulin receptor signaling pathway	23	2.61E-06
BPGO:0008543fibroblast growth factor receptor signaling pathway223.49E-09BPGO:0034142toll-like receptor 4 signaling pathway222.23E-08BPGO:0034300cell junction organization220.004663BPGO:0022617extracellular matrix disassembly220.0138599BPGO:0034060generation of precursor metabolites and energy220.0460089BPGO:0034162toll-like receptor 9 signaling pathway involved in phagocytosis211.01E-13BPGO:002244toll-like receptor 9 signaling pathway211.01E-09BPGO:0048015phosphatidylinositol-mediated signaling210.004608BPGO:0006644phosphatidylinositol-mediated signaling210.001544BPGO:000866G2/M transition of mitotic cell cycle210.0024742CCGO:0008575cellular_component321.93E-22CCGO:000829cytosol301.17E-15CCGO:0005654microtubule organizing center301.03E-13CCGO:0005615microtubule organizing center260.0031329MFGO:0003674molecular_function329.58E-29	BP	GO:0019221	cytokine-mediated signaling pathway	23	0.0327518
BPGO:0034142toll-like receptor 4 signaling pathway222.231-08BPGO:0034330cell junction organization223.30E-06BPGO:002257extracellular matrix disassembly220.0046663BPGO:0022617extracellular matrix disassembly220.0460089BPGO:0038096Fc-gamma receptor signaling pathway involved in phagocytosis211.01E-13BPGO:002224toll-like receptor 9 signaling pathway216.22E-07BPGO:0048015phosphatidylinositol-mediated signaling211.05E-06BPGO:0006928cellular component movement210.0001544BPGO:0006928G2/M transition of mitotic cell cycle210.0024742CCGO:0005575cellular_component305.11E-20CCGO:0043234protein complex301.17E-15CCGO:005654nucleoplasm301.03E-13CCGO:005815microtubule organizing center260.0031329MFGO:003674molecular_function325.38E-85MFGO:003674molecular_function325.38E-85	BP	GO:0008543	fibroblast growth factor receptor signaling pathway	22	3.49E-09
BPGO:0034330cell junction organization223.30E-06BPGO:006325chromatin organization220.0046663BPGO:0022617extracellular matrix disassembly220.0138599BPGO:0006091generation of precursor metabolites and energy220.0460089BPGO:0038096Fc-gamma receptor signaling pathway involved in phagocytosis211.01E-13BPGO:002224toll-like receptor 9 signaling pathway211.01E-09BPGO:0048015phosphatidylinositol-mediated signaling216.22E-07BPGO:006928cellular component movement219.77E-05BPGO:0006644phospholipid metabolic process210.001544BPGO:0005575cellular_component221.93E-22CCGO:005575cellular_component305.11E-20CCGO:005829cytosol301.17E-15CCGO:005829cytosol301.17E-13CCGO:005815nucleoplasm301.03E-13CCGO:005815nicrotubule organizing center260.0031329MFGO:003674molecular_function325.38E-85MFGO:003674molecular_function329.58E-29	BP	GO:0034142	toll-like receptor 4 signaling pathway	22	2.23E-08
BPCO:0006325chromatin organization220.0046663BPGO:0022617extracellular matrix disasembly220.0138599BPGO:0006091generation of precursor metabolites and energy220.0460089BPGO:0038096Fc-gamma receptor signaling pathway involved in phagocytosis211.01E-13BPGO:002224toll-like receptor signaling pathway216.22E-07BPGO:0048015phosphatidylinositol-mediated signaling211.05E-06BPGO:006928cellular component movement219.77E-05BPGO:0006644phospholipid metabolic process210.0024742CCGO:0005575cellular_component321.93E-22CCGO:005575cellular_component301.17E-15CCGO:005829cytosol301.17E-15CCGO:005815mucrouplax301.03E-13CCGO:005654nucleoplasm301.03E-13CCGO:005654incrotubule organizing center260.0031329MFGO:003674molecular_function325.38E-85MFGO:003674molecular_function329.58E-29	BP	GO:0034330	cell junction organization	22	3.30E-06
BPGO:0022617extracellular matrix disassembly220.0138599BPGO:0006091generation of precursor metabolites and energy220.0460089BPGO:0038096Fc-gamma receptor signaling pathway involved in phagocytosis211.01E-13BPGO:002224toll-like receptor 9 signaling pathway216.22E-07BPGO:0006928cellular component movement216.22E-07BPGO:0006928cellular component movement219.77E-05BPGO:000644phospholipid metabolic process210.0001544BPGO:000575cellular_component210.002742CCGO:0005875cellular_component305.11E-20CCGO:005829cytosol301.03E-13CCGO:0005654nucleoplasm301.03E-13CCGO:0005815microtubule organizing center260.0031329MFGO:0003674molecular_function325.38E-85MFGO:0003674molecular_function329.58E-29	BP	GO:0006325	chromatin organization	22	0.0046663
BPGO:0006091generation of precursor metabolites and energy220.0460089BPGO:0038096Fc-gamma receptor signaling pathway involved in phagocytosis211.01E-13BPGO:00224toll-like receptor 9 signaling pathway216.22E-07BPGO:000224toll-like receptor signaling pathway216.22E-07BPGO:0006928cellular component movement219.77E-05BPGO:0006644phospholipid metabolic process210.0001544BPGO:000575cellular_component210.0024742CCGO:000575cellular_component221.93E-22CCGO:0005829cytosol301.17E-15CCGO:0005654nucleoplasm301.03E-13CCGO:0005815microtubule organizing center260.0031329MFGO:0003674molecular_function329.58E-29	BP	GO:0022617	extracellular matrix disassembly	22	0.0138599
BPGO:0038096Fc-gamma receptor signaling pathway involved in phagocytosis211.01E-13BPGO:0024162toll-like receptor 9 signaling pathway211.01E-09BPGO:002224toll-like receptor signaling pathway216.22E-07BPGO:0048015phosphatidylinositol-mediated signaling211.05E-06BPGO:006928cellular component movement219.77E-05BPGO:0006644phospholipid metabolic process210.0001544BPGO:000575cellular_component210.0024742CCGO:000575cellular_component321.93E-22CCGO:0005829cytosol301.17E-15CCGO:0005854nucleoplasm301.03E-13CCGO:0005815microtubule organizing center260.0031329MFGO:0003674molecular_function329.58E-29	BP	GO:0006091	generation of precursor metabolites and energy	22	0.0460089
BPGO:0034162toll-like receptor 9 signaling pathway211.01E-09BPGO:0002224toll-like receptor signaling pathway216.22E-07BPGO:0048015phosphatidylinositol-mediated signaling211.05E-06BPGO:0006928cellular component movement219.77E-05BPGO:0006644phospholipid metabolic process210.0001544BPGO:000086G2/M transition of mitotic cell cycle210.0024742CCGO:000575cellular_component321.93E-22CCGO:0005829cytosol301.17E-15CCGO:0005654nucleoplasm301.03E-13CCGO:0005815microtubule organizing center260.0031329MFGO:003674molecular_function325.38E-85MFGO:0003674molecular_function329.58E-29	BP	GO:0038096	Fc-gamma receptor signaling pathway involved in phagocytosis	21	1.01E-13
BPGO:002224toll-like receptor signaling pathway216.22E-07BPGO:0048015phosphatidylinositol-mediated signaling211.05E-06BPGO:0006928cellular component movement219.77E-05BPGO:0006644phospholipid metabolic process210.0001544BPGO:000086G2/M transition of mitotic cell cycle210.0024742CCGO:000575cellular_component321.93E-22CCGO:0043234protein complex305.11E-20CCGO:0005829cytosol301.17E-15CCGO:0005654nucleoplasm301.03E-13CCGO:0005815microtubule organizing center260.0031329MFGO:003674molecular_function325.38E-85MFGO:003674molecular_function329.58E-29	BP	GO:0034162	toll-like receptor 9 signaling pathway	21	1.01E-09
BP GO:0048015 phosphatidylinositol-mediated signaling 21 1.05E-06 BP GO:0006928 cellular component movement 21 9.77E-05 BP GO:0006644 phospholipid metabolic process 21 0.0001544 BP GO:000086 G2/M transition of mitotic cell cycle 21 0.0024742 CC GO:0005575 cellular_component 32 1.93E-22 CC GO:0005829 protein complex 30 5.11E-20 CC GO:0005554 nucleoplasm 30 1.03E-13 CC GO:000554 microtubule organizing center 26 0.0031329 MF GO:0003674 molecular_function 32 5.38E-85	BP	GO:0002224	toll-like receptor signaling pathway	21	6.22E-07
BP GO:0006928 cellular component movement 21 9.77E-05 BP GO:0006644 phospholipid metabolic process 21 0.0001544 BP GO:000086 G2/M transition of mitotic cell cycle 21 0.0024742 CC GO:0005575 cellular_component 32 1.93E-22 CC GO:0043234 protein complex 30 5.11E-20 CC GO:005559 cytosol 30 1.03E-13 CC GO:0005654 nucleoplasm 30 1.03E-13 CC GO:0005815 microtubule organizing center 26 0.0031329 MF GO:0003674 molecular_function 32 5.38E-85	BP	GO:0048015	phosphatidylinositol-mediated signaling	21	1.05E-06
BP GO:0006644 phospholipid metabolic process 21 0.0001544 BP GO:000086 G2/M transition of mitotic cell cycle 21 0.0024742 CC GO:0005575 cellular_component 32 1.93E-22 CC GO:0005829 protein complex 30 5.11E-20 CC GO:0005554 nucleoplasm 30 1.03E-13 CC GO:0005815 microtubule organizing center 26 0.0031329 MF GO:0003674 molecular_function 32 5.38E-85	BP	GO:0006928	cellular component movement	21	9.77E-05
BP GO:000086 G2/M transition of mitotic cell cycle 21 0.0024742 CC GO:0005575 cellular_component 32 1.93E-22 CC GO:0043234 protein complex 30 5.11E-20 CC GO:0005829 cytosol 30 1.17E-15 CC GO:0005845 nucleoplasm 30 1.03E-13 CC GO:0005815 microtubule organizing center 26 0.0031329 MF GO:003674 molecular_function 32 5.38E-85	BP	GO:0006644	phospholipid metabolic process	21	0.0001544
CC GO:0005575 cellular_component 32 1.93E-22 CC GO:0043234 protein complex 30 5.11E-20 CC GO:0005829 cytosol 30 1.17E-15 CC GO:0005654 nucleoplasm 30 1.03E-13 CC GO:0005815 microtubule organizing center 26 0.0031329 MF GO:0003674 molecular_function 32 5.38E-85	BP	GO:000086	G2/M transition of mitotic cell cycle	21	0.0024742
CC GO:043234 protein complex 30 5.11E-20 CC GO:0005829 cytosol 30 1.17E-15 CC GO:0005654 nucleoplasm 30 1.03E-13 CC GO:0005815 microtubule organizing center 26 0.0031329 MF GO:003674 ion binding 32 5.38E-85	CC	GO:0005575	cellular_component	32	1.93E-22
CC GO:0005829 cytosol 30 1.17E-15 CC GO:0005654 nucleoplasm 30 1.03E-13 CC GO:0005815 microtubule organizing center 26 0.0031329 MF GO:0003674 ion binding 32 5.38E-85 MF GO:0003674 molecular_function 32 9.58E-29	CC	GO:0043234	protein complex	30	5.11E-20
CC GO:0005654 nucleoplasm 30 1.03E-13 CC GO:0005815 microtubule organizing center 26 0.0031329 MF GO:0003674 ion binding 32 5.38E-85 MF GO:0003674 molecular_function 32 9.58E-29	CC	GO:0005829	cytosol	30	1.17E-15
CC GO:0005815 microtubule organizing center 26 0.0031329 MF GO:0043167 ion binding 32 5.38E-85 MF GO:0003674 molecular_function 32 9.58E-29	CC	GO:0005654	nucleoplasm	30	1.03E-13
MF GO:0043167 ion binding 32 5.38E-85 MF GO:0003674 molecular_function 32 9.58E-29	CC	GO:0005815	microtubule organizing center	26	0.0031329
MF GO:0003674 molecular_function 32 9.58E-29	MF	GO:0043167	ion binding	32	5.38E-85
	MF	GO:0003674	molecular_function	32	9.58E-29

Int. J. Med. Sci. 2020, Vol. 17

GO ID		GO (name)	Degree	P value
MF	GO:0001071	nucleic acid binding transcription factor activity	30	1.33E-22
MF	GO:0000988	protein binding transcription factor activity	27	3.47E-21
MF	GO:0019899	enzyme binding	27	1.21E-20
MF	GO:0008092	cytoskeletal protein binding	28	1.25E-16
MF	GO:0030234	enzyme regulator activity	29	2.03E-10
MF	GO:0022857	transmembrane transporter activity	28	9.52E-05
MF	GO:0030674	protein binding, bridging	23	0.0343038



Figure 4. Significantly changed KEGG pathways of predicted target genes of deregulated miRNAs between HepG2/IR and HepG2 cells. The *y*-axis shows KEGG category and the x-axis shows -lgP. The larger -lgP indicated a smaller P value. -lgP represent the negative logarithm of the P value.



Figure 5. miRNA-gene network showing the interactions between key miRNAs and the predicted hub genes. The square nodes represent miRNAs (red nodes denote up-regulated miRNAs, green nodes denote down-regulated miRNAs), circular nodes represent hub target genes (purple nodes denote crucial and hub target genes with degree >4).



Figure 6. miRNA-GO network showing the interactions between key miRNAs and the hub GO. The square nodes represent miRNAs (red nodes denote up-regulated miRNAs, green nodes denote down-regulated miRNAs), circular nodes represent hub GO with degree>25 (purple nodes denote tumor related hub GO).



Figure 7. miRNA-KEGG network showing the interactions between key miRNAs and the hub KEGG pathway. The square nodes represent miRNAs (red nodes denote up-regulated miRNAs, green nodes denote down-regulated miRNAs), circular nodes represent hub KEGG pathway with degree>30 (purple nodes denote tumor related hub KEGG).

 Table 6. Crucial miRNAs in the miRNA-KEGG network (degree >10)

miRNA	Degree
hsa-miR-4492	45
hsa-miR-5195-3p	44
hsa-miR-641	44
hsa-miR-4505	43
hsa-miR-6870-5p	43
hsa-miR-6848-5p	42
hsa-miR-6779-5p	41
hsa-miR-134-5p	39
hsa-miR-6780b-5p	39
hsa-miR-6795-5p	39
hsa-miR-7111-5p	39
hsa-miR-1231	38
hsa-miR-6846-5p	38
hsa-miR-4793-5p	37
hsa-miR-6757-5p	37
hsa-miR-3613-5p	34
hsa-miR-3935	32
hsa-miR-6813-5p	32
hsa-miR-6782-5p	28
hsa-miR-6805-5p	28
hsa-miR-6132	27
hsa-miR-6085	21
hsa-miR-3937	15
hsa-miR-3180	14

miRNA mainly performs its regulatory function through its targets. Functions of these predicted target genes significantly enriched in the processes related with metabolic, biosynthetic, transcriptional and protein modification etc., biological regulatory mechanisms were integrated in several main KEGG pathways, most of which are cancer-related pathways, such as Ras signaling pathway, Hippo signaling pathway, ErbB signaling pathway, other types of O-glycan biosynthesis etc. These pathways regulate cell proliferation, adhesion, migration,

674

differentiation, evasion and angiogenesis [28-31]. The most significant KEGG pathway was other types of O-glycan biosynthesis. It was believed that the aberrant O-glycan of cell surface influence the adhesion of cancer cells to the endothelium, promoting tumor migration, invasion and favoring cancer cells epithelial-to-mesenchymal transition (EMT). During malignancy progression, tumor cells prevalently stimulate expression of O-glycans that are normally present on embryonic tissues, but not on well-differentiated adult tissues [31,41,42]. This indicates that these dysregulated miRNAs and their target genes may be involving in the tumorigenesis, drug resistance and tumor progression of the insulin resistant HCC cell line.

We also constructed a network which connected the differentially expressed miRNAs to their target genes, also to GO and KEGG enrichment. The network revealed the biological functions and contributed to better understanding of the role of dysregulated miRNAs. In these networks, certain miRNAs functioned as network hubs, such as miR-641, miR-6870-5p, miR-7111-5p, miR-4505, miR-4492, and miR-5195-3p. Among these miRNAs, miR-641 was one of the most active miRNAs in the network which targeting 52 genes, 114 GO terms and 44 KEGG pathways. In accord with previous reports, miR-641 was confirmed down-regulated in our present study, suggesting that it might be related with impaired drug sensitivity, migration and adhesion in insulin resistant HepG2 cells. Additional studies are required to elucidate the detailed role of miR-641 in insulin resistant HCC.

Table 7. Crucial KEGGs in the miRNA-KEGG network (degree >30)

KEGG ID	KEGG_Term	Degree	P value
hsa04010	MAPK signaling pathway	97	0.008968411
hsa04014	Ras signaling pathway	87	0.003145657
hsa04144	Endocytosis	85	0.004307909
hsa04015	Rap1 signaling pathway	84	0.0045072
hsa04024	cAMP signaling pathway	76	0.035393834
hsa05205	Proteoglycans in cancer	73	0.000299322
hsa04921	Oxytocin signaling pathway	68	0.002905436
hsa04261	Adrenergic signaling in cardiomyocytes	65	0.000450147
hsa04390	Hippo signaling pathway	61	0.003145657
hsa04360	Axon guidance	56	0.008176788
hsa04550	Signaling pathways regulating pluripotency of stem cells	56	0.006210047
hsa04514	Cell adhesion molecules (CAMs)	56	0.001916405
hsa04728	Dopaminergic synapse	54	0.0194252
hsa04152	AMPK signaling pathway	53	0.00777182
hsa04611	Platelet activation	51	0.017005802
hsa04919	Thyroid hormone signaling pathway	49	0.035095754
hsa04724	Glutamatergic synapse	48	0.003145657
hsa04668	TNF signaling pathway	44	0.031542367
hsa04915	Estrogen signaling pathway	42	0.001916405
hsa04723	Retrograde endocannabinoid signaling	41	0.01974073

KEGG ID	KEGG_Term	Degree	P value
hsa04750	Inflammatory mediator regulation of TRP channels	41	0.01974073
hsa04670	Leukocyte transendothelial migration	40	0.044378808
hsa04012	ErbB signaling pathway	40	0.002905436
hsa04666	Fc gamma R-mediated phagocytosis	39	0.034514602
hsa05414	Dilated cardiomyopathy	35	0.044378808
hsa04540	Gap junction	34	0.029084915
hsa04720	Long-term potentiation	32	0.0110171
hsa04350	TGF-beta signaling pathway	31	0.0045072



Figure 8. Validation of the microarray results by qRT-PCR. Expression level of the dysregulated miRNAs were shown in the figure. All miRNAs exhibited statistically significant changes in the HepG2/IR cells compared with its parental cells. Relative expression levels were calculated by $2^{-\Delta C_{t}}$ method after the (cycle threshold) Ct value (power amplification knee point) was obtained. Experiments were repeated three times with similar results, and the results are presented as mean±SD of triplicate experiments. *P<0.05, ** P<0.01.

The miRNA networks analysis also revealed a range of hub genes (such as KSR2, SYNGAP1), crucial KEGG pathways (Ras signaling pathway, MAPK signaling pathway), and crucial GO (Cellular nitrogen compound metabolic process, Biosynthetic process, Biological process) and most of which were involved in tumorigenesis, drug resistance and poor prognosis of cancer patients [43-48]. Kinase Suppressor of Ras 2 (KSR2) is a molecular scaffold that regulate the intensity and duration of the Ras/Raf/MEK/ERK/ MAPK kinase cascade to facilitate energy consumption and expenditure [49,50]. Deletion of KSR2 leads to impair the oxidation of fatty acids and increase their storage as triglycerides, reduced basal metabolic rate thus contributing to obesity and insulin resistance [49,51]. KSR2 was also reported as an activator to stimulate tumor cell transformation [45]. Ojha R et al declared that it interacts with the endoplasmic reticulum (ER) stress chaperone (GRP78) and facilitated ER translocation which drove therapy resistance in BRAF-Mutant melanoma [46]. Our present study revealed that as a predicted target gene KSR2 was regulated by eight miRNAs including 7 up-regulated miRNAs (miR-4492, miR-4505, miR-6132, miR-6779-5p, miR-6780b-5p, miR-6870-5p, miR-7111-5p) and 1 down-regulated miRNA (miR-641). It was involved in many GO categories such as cellular protein modification process, cellular_component, cytosol, ion binding, molecular_function, cellular protein modification process, and participated in Ras signaling KEGG pathway. In our previous study [6-8], we found that insulin resistance contributes to multidrug resistance in HCC cells via activation of the ER stress, suggesting that KSR2 may be involved in therapy resistance in insulin resistant HCC. The expression of KSR2 and its relationship with correlated miRNAs need to be further validated.

cytosolic protein SYNGAP1/RASA5 The (SYNaptic GTPase Activating Protein 1) [48,52] encoded by SYNGAP1 gene was reported as a Ras signaling suppressor comprised in RASA subfamily (Ras GAPs) [53]. It was known that Ras GAPs can inactivate RAS signaling and inhibit oncogenic transformation initiated by RAS. Suppression of Ras GAPs may constitute an additional mechanism whereby aberrant *Ras* activation promotes tumorigenesis [47,54]. Li L et al [48] declared that expression of SYNGAP1/RASA5 inhibited tumor cell migration/ invasion and growth in mouse model, functioning as a tumor suppressor. Conversely, knockdown of SYNGAP1/RASA5 enhanced Ras signaling to promote tumor cell growth. SYNGAP1/RASA5 also inhibited EMT through regulating actin reorganization. Thus, epigenetic inactivation of SYNGAP1/ RASA5 contributing to hyperactive RAS signaling is involved in Ras-driven human oncogenesis. In our current study, SYNGAP1 was predicted being targeted only by up-regulated miRNAs including miR-4492,

miR-3180, miR-4505, miR-6085, miR-6795-5p, miR-6805-5p, miR-6870-5p miR-7111-5p. It was involved in two GO categories (cellular_component and molecular_function) and participated in Ras signaling pathway. The results suggested that SYNGAP1 might be reduced expression in insulin resistant HepG2 cells. As we known, Ras signaling pathway is often deregulated in tumors through inactivation of Ras inhibitors, SYNGAP1 acts as a tumor suppressor negatively regulated the Ras signaling pathway in cancer. Decreasing expression of SYNGAP1 indicated the enhanced migration, invasion and multidrug resistance in the insulin resistant HCC. Further study should be addressed to validate the expression, regulatory miRNAs, and function of SYNGAP1 in insulin resistant HCC.

In conclusion, our study compared the miRNA expression profile in the insulin resistant HCC cells with its parental cells and identified the differentially expressed miRNAs, which provides information for further understanding of the molecular mechanisms of insulin resistance HCC cells in tumor progression and drug resistance.

Supplementary Material

Supplementary tables. http://www.medsci.org/v17p0664s1.zip

Acknowledgements

This work was supported by the National Natural Science Foundation of China (81602622), Internationally Technological Cooperation Project of Gansu Province (18YF1WA117), Scientific Research Project of Gansu Medical and Health Industry (GSWSKY2016-14), Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital (CY2018-MS11), the Fundamental Research Funds for the Central Universities (lzujbky-2017-81).

Contribution

L.J. conceived and designed the experiments. L.Z., M.L, L.L. and Y.J. performed the experiments. C.Y., D.F, L.J. and P.H. analyzed the data. L.J., C.Y. and L.L. wrote the paper. All authors read and approved the final manuscript.

Competing Interests

The authors have declared that no competing interest exists.

References

 Siegel R L, Miller K D, Jemal A. Cancer statistics. CA: a cancer journal for clinicians, 2015, 65(1): 5-29. hepatology, 1993, 18(2): 168-172.
Leclercq I A, Morais A D S, Schroyen B, et al. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences[J]. Journal of hepatology, 2007, 47(1): 142-156.

2.

- Feng Y H, Lin C Y, Huang W T, et al. Diabetes mellitus impairs the response to intra-arterial chemotherapy in hepatocellular carcinoma[J]. Medical Oncology, 2011, 28(4): 1080-1088.
- Mantovani A, Targher G. Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease[J]. Annals of translational medicine. 2017;5(13).
- Li L, Li G, Wei H, et al. The endoplasmic reticulum stress response is associated with insulin resistance-mediated drug resistance in HepG2 cells[J]. Neoplasma, 2015, 62(2): 180-190.
- Liu X, Li L, Li J, et al. Insulin resistance contributes to multidrug resistance in HepG2 cells via activation of the PERK signaling pathway and upregulation of Bcl-2 and P-gp[J]. Oncology reports, 2016, 35(5): 3018-3024.
- Li L, Liu X, Zhou L, et al. Autophagy Plays a Critical Role in Insulin Resistance-Mediated Chemoresistance in Hepatocellular Carcinoma Cells by Regulating the ER Stress[J]. Journal of Cancer, 2018, 9(23): 4314.
- Li L J, Li G D, Wei H L, et al. Insulin resistance reduces sensitivity to Cis-platinum and promotes adhesion, migration and invasion in HepG2 cells[J]. Asian Pac J Cancer Prev, 2014, 15(7): 3123-3128.
- Oliveto S, Mancino M, Manfrini N, et al. Role of microRNAs in translation regulation and cancer[J]. World journal of biological chemistry, 2017, 8(1): 45.
- 11. Lu J, Getz G, Miska E A, et al. MicroRNA expression profiles classify human cancers[J]. nature, 2005, 435(7043): 834.
- Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs[J]. Drug resistance updates, 2007, 10(1-2): 59-67.
- Allen K E, Weiss G J. Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics[J]. Molecular cancer therapeutics, 2010, 9(12): 3126-3136.
- Kabir T D, Ganda C, Brown R M, et al. A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma[J]. Hepatology, 2018, 67(1): 216-231.
- Xia H, Ooi L L P J, Hui K M. MicroRNA-216a/217-induced epithelialmesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer[J]. Hepatology, 2013, 58(2): 629-641.
- Meng W, Tai Y, Zhao H, et al. Downregulation of miR-33a-5p in hepatocellular carcinoma: a possible mechanism for chemotherapy resistance[J]. Medical science monitor: international medical journal of experimental and clinical research, 2017, 23: 1295.
- Yang X, Yin J, Yu J, et al. miRNA-195 sensitizes human hepatocellular carcinoma cells to 5-FU by targeting BCL-w[J]. Oncology reports, 2012, 27(1): 250-257.
- Long L, Xiang H, Liu J, et al. ZEB1 mediates doxorubicin (Dox) resistance and mesenchymal characteristics of hepatocarcinoma cells[J]. Experimental and molecular pathology, 2019, 106: 116-122.
- Vlachos I S, Zagganas K, Paraskevopoulou M D, et al. DIANA-miRPath v3. 0: deciphering microRNA function with experimental support[J]. Nucleic acids research, 2015, 43(W1): W460-W466.
- Czech M P. Insulin action and resistance in obesity and type 2 diabetes[J]. Nature medicine, 2017, 23(7): 804-814.
- Ratziu V, Goodman Z, Sanyal A. Current efforts and trends in the treatment of NASH[J]. Journal of hepatology, 2015, 62(1): S65-S75.
- 22. Ahmed A, Wong R J, Harrison S A. Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes[J]. Clinical Gastroenterology and Hepatology, 2015, 13(12): 2062-2070.
- Castera L, Vilgrain V, Angulo P. Noninvasive evaluation of NAFLD[J]. Nature reviews Gastroenterology & hepatology, 2013, 10(11): 666.
- Haas J T, Francque S, Staels B. Pathophysiology and mechanisms of nonalcoholic fatty liver disease[J]. Annual review of physiology, 2016, 78: 181-205.
- Moschen A R, Kaser S, Tilg H. Non-alcoholic steatohepatitis: a microbiota-driven disease[J]. Trends in Endocrinology & Metabolism, 2013, 24(11): 537-545.
- Giovannucci E, Harlan D M, Archer M C, et al. Diabetes and cancer: a consensus report[J]. CA: a cancer journal for clinicians, 2010; 60(4): 207-221.
- El-Serag H B, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence[J]. Clinical Gastroenterology and Hepatology, 2006; 4(3): 369-380.
- Coggins G E, Farrel A, Rathi K S, et al. YAP1 mediates resistance to MEK1/2 inhibition in neuroblastomas with hyperactivated RAS signalling[J]. Cancer Research, 2019.
- 29. Ma X, Lu J Y, Moraru A, et al. A novel regulator of ER Ca 2+ drives Hippo-mediated tumorigenesis[J]. Oncogene, 2019: 1-10.
- Ghaemi Z, Mowla S J. MicroRNA-326 functions as a tumor suppressor in breast cancer by targeting ErbB/PI3K signaling pathway[J]. Frontiers in oncology, 2019; 9: 653.
- Thomas D, Sagar S, Caffrey T, et al. Truncated O-glycans promote epithelialto-mesenchymal transition and stemness properties of pancreatic cancer cells[J]. Journal of cellular and molecular medicine, 2019; 23(10): 6885-6896.

- Liu Q, Wu Y, Xiao J, et al. Long non-coding RNA Prostate Cancer-Associated Transcript 7 (PCAT7) induces poor prognosis and promotes tumorigenesis by inhibiting miR-134-5p in Non-Small-Cell Lung (NSCLC)[J]. Medical science monitor: international medical journal of experimental and clinical research, 2017;23: 6089.
- Chi J, Liu T, Shi C, et al. Long non-coding RNA LUCAT1 promotes proliferation and invasion in gastric cancer by regulating miR-134-5p/YWHAZ axis[J]. Biomedicine & Pharmacotherapy, 2019; 118: 109201.
- Liu Y, Tao Z, Qu J, et al. Long non-coding RNA PCAT7 regulates ELF2 signaling through inhibition of miR-134-5p in nasopharyngeal carcinoma[J]. Biochemical and biophysical research communications, 2017; 491(2): 374-381.
- Fu D, Lu C, Qu X, et al. LncRNA TTN-AS1 regulates osteosarcoma cell apoptosis and drug resistance via the miR-134-5p/MBTD1 axis[J]. Aging, 2019; 11.
- Kong Q, Shu N, Li J, et al. miR-641 functions as a tumor suppressor by targeting MDM2 in human lung cancer[J]. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, 2018; 26(5): 735-741.
- Yao R, Zheng H, Wu L, et al. miRNA-641 inhibits the proliferation, migration, and invasion and induces apoptosis of cervical cancer cells by directly targeting ZEB1[J]. OncoTargets and therapy, 2018, 11: 8965.
- Hinske L C, Heyn J, Hübner M, et al. Intronic miRNA-641 controls its host Gene's pathway PI3K/AKT and this relationship is dysfunctional in glioblastoma multiforme[J]. Biochemical and biophysical research communications, 2017; 489(4): 477-483.
- Chen J, Cui J, Guo X, et al. Increased expression of miR-641 contributes to erlotinib resistance in non-small-cell lung cancer cells by targeting NF 1[J]. Cancer medicine, 2018; 7(4): 1394-1403.
- Yan L, Liu J, Zhao Y, et al. Suppression of miR-628-3p and miR-641 is involved in rifampin-mediated CYP3A4 induction in HepaRG cells[J]. Pharmacogenomics, 2017;18(1): 57-64.
- Tsai C H, Tzeng S F, Chao T K, et al. Metastatic progression of prostate cancer is mediated by autonomous binding of galectin-4-O-glycan to cancer cells[J]. Cancer research, 2016;76(19): 5756-5767.
- Häuselmann I, Borsig L. Altered tumor-cell glycosylation promotes metastasis[J]. Frontiers in oncology, 2014;4: 28.
- McCubrey J A, Steelman L S, Chappell W H, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance[J]. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 2007; 1773(8): 1263-1284.
- McKay M M, Morrison D K. Integrating signals from RTKs to ERK/MAPK[J]. Oncogene, 2007; 26(22): 3113.
- Fernandez M R, Henry M L D, Lewis R E. Kinase suppressor of Ras 2 (KSR2) regulates tumor cell transformation via AMPK[J]. Molecular and cellular biology, 2012; 32(18): 3718-3731.
- Ojha R, Leli N M, Onorati A, et al. ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma[J]. Cancer discovery, 2019; 9(3): 396-415.
- Grewal T, Koese M, Tebar F, et al. Differential regulation of RasGAPs in cancer[J]. Genes & cancer, 2011; 2(3): 288-297.
- Li L, Fan Y, Huang X, et al. Tumor Suppression of Ras GTPase-Activating Protein RASA5 through Antagonizing Ras Signaling Perturbation in Carcinomas[J]. iScience, 2019;21: 1.
- Costanzo-Garvey D L, Pfluger P T, Dougherty M K, et al. KSR2 is an essential regulator of AMP kinase, energy expenditure, and insulin sensitivity[J]. Cell metabolism, 2009; 10(5): 366-378.
- Dougherty M K, Ritt D A, Zhou M, et al. KSR2 is a calcineurin substrate that promotes ERK cascade activation in response to calcium signals[J]. Molecular cell. 2009; 34(6): 652-662.
- Pearce LR, Atanassova N, Banton M C, et al. KSR2 mutations are associated with obesity, insulin resistance, and impaired cellular fuel oxidation[J]. Cell. 2013; 155(4): 765-777.
- Walkup W G, Washburn L, Sweredoski M J, et al. Phosphorylation of synaptic GTPase-activating protein (synGAP) by Ca2+/calmodulindependent protein kinase II (CaMKII) and cyclin- dependent kinase 5 (CDK5) alters the ratio of its GAP activity toward Ras and Rap GTPases [J]. J Biol Chem. 2015;290(8):4908-27.
- Maertens O, Cichowski K. An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer[J]. Advances in biological regulation. 2014; 55: 1-14.
- Bernards A, Settleman J. GAPs in growth factor signalling[J]. Growth factors. 2005;23(2): 143-149.
- Qiu Z, He G. MicroRNA-134 functions as a tumor suppressor gene in gastriccancer, Am. J. Transl. Res. 2016;8 (10): 4320-4328.
- Shuang T, Wang M, Zhou Y, et al. NF-kappaB1, c-Rel, and ELK1 inhibit miR-134 expression leading to TAB1 upregulation in paclitaxel-resistant human ovarian cancer. Oncotarget. 2017; 8(15): 24853-24868.